You are here

Innovation Theaters Schedule

Exhibit Hall Booths #2105, 2123, 2143

Grab a bite and get informed at the Innovation Theater. Don’t miss out on participating in a non-CME informative lunch or snack break discussion about the latest clinical information as it relates to a specific disease state. Innovation Theater presentations are independently organized and are not an official part of the Internal Medicine Meeting 2017 education program.

 

Thursday, March 30

Morning Break 10:30-11:15 a.m. Booth 2105
Supported by Sanofi Regeneron
 

Morning Break 10:30-11:15 a.m. Booth 2123
Cardiovascular Health and Prevention with Omega-3s in Modern Day Practice
Supported by DSM Nutritional Products

Benefits of omega-3 polyunsaturated fatty acids have been debated, however, major recent clinical trials and large meta-analyses demonstrating overall health and cardiovascular benefits continue to emerge. Effective doses of omega-3s, specifically EPA and DHA, can help produce optimal blood levels, providing substantial promise for heart and general health benefit.

Carl “Chip” Lavie, MD, FACC
New Orleans, LA

 

Lunch 1-1:45 p.m. Booth 2105
Influenza in Seniors: Helping to Protect a Vulnerable Population

Supported by Sanofi Pasteur

 

Lunch 1-1:45 p.m. Booth 2123
Breakthrough Therapies Transforming HCV Treatment For Patients With All Genotypes
Supported by Gilead Sciences

 

Lunch 1-1:45 p.m. Booth 2143
IBS-D: Understanding the Patient, the Diagnosis, and the Treatment Option
Supported by Salix Pharmaceuticals, Inc.

Mark Pimentel, MD will review IBS-D and the patient, diagnosis, and treatment option.

Mark Pimentel, MD, FRCP(C)
Los Angeles, CA

 

Afternoon Break 3:45-4:30 p.m. Booth 2105
A Change of Heart: Achieving Best Outcomes When Caring for African American HF Patients
Supported by Arbor Pharmaceuticals

This program will review valuable information and treatment recommendations from current clinical guidelines for the appropriate care of African American patients with heart failure.

 

Friday, March 31

 

Morning Break 10:30-11:15 a.m. Booth 2105
Repatha® (evolocumab): A Focused Clinical Review
Supported by Amgen

Reduction in circulating levels of low-density lipoprotein cholesterol (LDL-C) remains fundamental to major cholesterol treatment guidelines and recommendations from medical organizations. This program will review a current therapy for additional LDL-C lowering.

Michael J. Bloch, MD, FACP, FASH, FSVM, FNLA

 

Morning Break 10:30-11:15 a.m. Booth 2123
Supported by Novartis Pharmaceuticals Corporation

 

Lunch 1-1:45 p.m. Booth 2105
Thrombosis: AFib & DVT/PE - An Exploration in Risk Reduction
Supported by Janssen Pharmaceuticals, Inc.

 

Lunch 1-1:45 p.m. Booth 2123
Current Approaches to Heart Failure Management
Supported by Novartis Pharmaceuticals Corporation

Heart failure (HF) is a complex clinical syndrome with high mortality, morbidity, and hospitalization rates. HF treatment goals and management approaches vary based on disease progression and other factors. This educational program will review HF treatment guidelines and discuss practical approaches to guideline implementation.

 

Lunch 1-1:45 p.m. Booth 2143
The Quality, Safety and Value Movements Converge to Transform Healthcare
Supported by Humana

Humana’s Chief Medical Officer, Roy Beveridge, MD, hosts a physician panel discussion on how quality, safety, and the push to value are transforming healthcare. Expert panelists include Robert Wachter, MD, global leader in healthcare safety, quality, policy and IT, and best-selling author, “The Digital Doctor: Hope, Hype and Harm at the Dawn of Medicine’s Computer Age.”

Roy Beveridge, MD
Louisville, KY
Robert Wachter, MD
San Francisco, CA

 

Afternoon Break 3:45-4:15 p.m. Booth 2105
The Challenge of Improving Glycemic Control in your Adult Patients with T2DM
Supported by Sanofi

Steven Edelman, MD
San Diego, CA

Jeremy Pettus, MD
San Diego, CA